Cas No.Product NameDescription
873837-23-1BMS-599626 HClBMS-599626 (BMS-599626; AC480) is a highly selective pan-HERKinase inhibitor with IC50 of 20 and 30 nM for the inhibition of HER1and HER2, respectively.
130798-51-5MDL-29951MDL-29951 is a novel glycine antagonist of NMDA receptor activation (Ki=0.14 mM, [3H]glycine binding) in vitro and in vivo.
170449-18-0AG-1478.hclAG-1478 is high selective over ErbB2 and PDGFR with IC50 of >100 μM.
184475-35-2GefitinibGefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.
133550-30-8AG-490AG-490 is a selective inhibitor of EGF receptor tyrosine kinase (IC50 values are 2 and 13.5 μM for EGFR and ErbB2 respectively). Inhibitor of JAK2, JAK3/STAT, JAK3/AP-1 and JAK3/MAPK pathways and potently inhibits cytokine-independent cell growth in vitro and tumor cell invasion in vivo.
439081-18-2AfatinibAfatinib (BIBW2992) is an irreversible EGFR/Neu inhibitor with an IC50 of 14 nM. Afatinib is a potent inhibitor of EGFR phosphorylation.
388082-78-8Lapatinib DitosylateLapatinib Ditosylate is a selective and effective inhibitor of ErbB-2 and EGFR dual tyrosine kinases.
857876-30-3Motesanib DiphosphateMotesanib Diphosphate (AMG-706) is a potent ATP-competitive inhibitor of VEGFR1/2/3 with IC50 of 2 nM/3 nM/6 nM, respectively; similar activity against Kit, ~10-fold more selective for VEGFR than PDGFR and Ret.
698387-09-6NeratinibNeratinib (HKI-272) is an orally available, irreversible tyrosine kinase inhibitor with IC50 of 59 nM and 92 nM for HER2 and EGFR, respectively.
443913-73-3VandetanibVandetanib is an anti-cancer drug that is used for the treatment of certain tumours of thethyroid gland.
1012054-59-9CUDC-101CUDC-101 is a potent multitargeted HDAC, EGFR and HER2 inhibitor with IC50 of 4.4, 2.4, and 15.7 nM, respectively.
451492-95-8AV-412AV-412(MP-412) is a potent dual inhibitor of EGFR and ErbB2(IC50=19 nM) tyrosine kinases, including the mutant EGFR(L858R IC50=0.51 nM, T790M IC50=0.79 nM); inhibits autophosphorylation of EGFR and ErbB2 with IC(50) of 43 and 282 nM, respectively.
497839-62-0AEE788AEE788 is a potent inhibitor of EGFR and HER2/ErbB2 with IC50 of 2 nM and 6 nM, less potent to VEGFR2/KDR, c-Abl, c-Src, and Flt-1, does not inhibit Ins-R, IGF-1R, PKCα and CDK1.
1214265-57-2WZ8040WZ8040 is an irreversiblely EGFR T790M inhibitor (IC50<10nM).
257933-82-7PelitinibPelitinib is a selective, irreversible inhibitor of the epidermal growth factor receptor (EGFR).
183321-86-0CP 373420OSI-420 is the major metabolite of Erlotinib in human plasma.
1213269-23-8WZ4002WZ4002 is an EGFR T790M inhibitor(IC50<20nM).
1110813-31-4DacomitinibDacomitinib(PF299804) is a potent, orally available, irreversible tyrosine kinase HER 1 (EGFR), HER2 and HER4 inhibitor with IC50 of 6, 45.7 and 73.7 nM for EGFR, ERBB2 and ERBB4, respectively.
183319-69-9Erlotinib HClErlotinib is a directly acting inhibitor of human EGFR tyrosine kinase with an IC50 of 2 nM.
848942-61-0AZD-8931AZD8931 is an ATP competitive and reversible inhibitor of EGFR (ErbB-1), Neu (ErbB-2) and ErbB-3 (the IC50 values are 4 nM, 3 nM and 4 nM, respectively).

First Previous Next End   Jump to  Page
Cell Cycle/Checkpoint
Angiogenesis/Tyrosine Kinase
Apoptosis Pathway
Aurora/Ksp Pathway
MAPK Pathway
Hormone Pathay
Proteases/HSP90/HSP70 Pathway
Wnt/Hedgehog/Notch Pathway
Jak/Stat Pathway
Ca/cAMP/Lipid Signaling Pathway
Neuro Signaling Pathway
TGF-beta/Smad Signaling Pathway
GPCR Pathway
Ion channel Pathway
Cytochrome P450 Pathway
Others Pathway